The story of Sildenafil presents a complex picture for those considering investment. While the initial launch generated massive returns, the end of its patent opened the floodgates to cheaper versions, dramatically eroding market share. Adult This poses a particular challenge for drug manufacturers relying on related blockbuster offerings, suggesti

The legacy of Viagra, and its developer copyright, presents a complex case study for investors. Initially a blockbuster drug, producing billions in revenue , its patent expiration created a wave of generic competition , significantly impacting its market share . While specific pharmaceutical companies may seek to capitalize on related treatments ,